These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16764044)

  • 1. Proceedings of the 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassemia and Other Diseases. Part 1. Taichung, Taiwan. April 22-26, 2005.
    Hemoglobin; 2006; 30(1):63-137. PubMed ID: 16764044
    [No Abstract]   [Full Text] [Related]  

  • 2. Report on the proceedings of the 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassemia and Other Diseases at Taichung, Taiwan, April 22-26, 2005.
    Peng CT; Fucharoen S; Kontoghiorghes GJ; Tsai CH
    Hemoglobin; 2006; 30(1):63-8. PubMed ID: 16540418
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings of the 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassaemia and other Diseases, part 2. Taichung, Taiwan, April 22-26, 2005.
    Hemoglobin; 2006; 30(2):183-347. PubMed ID: 16903005
    [No Abstract]   [Full Text] [Related]  

  • 4. Proceedings of the 18th International Conference on Chelation (ICOC). December 13-16, 2008, Athens, Greece.
    Hemoglobin; 2010 Jun; 34(3):199-331. PubMed ID: 21305716
    [No Abstract]   [Full Text] [Related]  

  • 5. Proceedings of the 17th International Conference on Chelation (ICOC) for the Treatment of Thalassemia, Cancer and Other Diseases Related to Metal and Free Radical Imbalance and Toxicity. November 2007. Shenzhen, China.
    Hemoglobin; 2009; 33(5):283-397. PubMed ID: 20052787
    [No Abstract]   [Full Text] [Related]  

  • 6. The 18th ICOC Proceedings in Athens, Greece: New breakthrough in thalassemia leading to the complete treatment of iron overload and to hundreds of patients achieving and maintaining normal body iron stores. Ethical questions on chelation therapy.
    Kontoghiorghes GJ
    Hemoglobin; 2010 Jun; 34(3):199-203. PubMed ID: 20524809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An oral treatment for iron overload in thalassemia?
    Kowdley KV; Tavill AS
    Hepatology; 1996 Feb; 23(2):380-2. PubMed ID: 8591869
    [No Abstract]   [Full Text] [Related]  

  • 9. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral iron chelating drugs: coming but not yet ready for clinical use.
    Hershko C
    Br Med J (Clin Res Ed); 1988 Apr; 296(6629):1081-2. PubMed ID: 3132216
    [No Abstract]   [Full Text] [Related]  

  • 12. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferiprone for thalassaemia.
    Pippard MJ; Weatherall DJ
    Lancet; 2000 Oct; 356(9239):1444-5. PubMed ID: 11052617
    [No Abstract]   [Full Text] [Related]  

  • 15. The proceedings of the 19Th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload.
    Kontoghiorghes GJ
    Hemoglobin; 2011; 35(3):181-5. PubMed ID: 21599430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining two orally active iron chelators for thalassemia.
    Berdoukas V; Carson S; Nord A; Dongelyan A; Gavin S; Hofstra TC; Wood JC; Coates T
    Ann Hematol; 2010 Nov; 89(11):1177-8. PubMed ID: 20217085
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
    Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.
    Evangeli M; Mughal K; Porter JB
    Hemoglobin; 2010 Jun; 34(3):305-21. PubMed ID: 20524820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
    Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.